Journal
ONCOGENE
Volume 28, Issue 44, Pages 3880-3891Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2009.242
Keywords
anthracyclines; mtDNA; mitochondria; nucleoids; doxorubicin; mitofusin
Funding
- MRC/Wellcome Trust
- MRC [G0500695] Funding Source: UKRI
- Medical Research Council [G0500695] Funding Source: researchfish
Ask authors/readers for more resources
Many anticancer drugs, such as doxorubicin (DXR), intercalate into nuclear DNA of cancer cells, thereby inhibiting their growth. However, it is not well understood how such drugs interact with mitochondrial DNA (mtDNA). Using cell and molecular studies of cultured cells, we show that DXR and other DNA intercalators, such as ethidium bromide, can rapidly intercalate into mtDNA within living cells, causing aggregation of mtDNA nucleoids and altering the distribution of nucleoid proteins. Remodelled nucleoids excluded DXR and maintained mtDNA synthesis, whereas non-remodelled nucleoids became heavily intercalated with DXR, which inhibited their replication, thus leading to mtDNA depletion. Remodelling was accompanied by extensive mitochondrial elongation or interconnection, and was suppressed in cells lacking mitofusin 1 and optic atrophy 1 (OPA1), the key proteins for mitochondrial fusion. In contrast, remodelling was significantly increased by p53 or ataxia telangiectasia mutated inhibition (ATM), indicating a link between nucleoid dynamics and the genomic DNA damage response. Collectively, our results show that DNA intercalators can trigger a common mitochondrial response, which likely contributes to the marked clinical toxicity associated with these drugs. Oncogene (2009) 28, 3880-3891; doi:10.1038/onc.2009.242; published online 17 August 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available